NexACT enables rectal delivery of biologics, say Apricus Bio
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
Elan mulls hiving-off drug delivery business again
Irish drugmaker Elan has once again raised the possibility of selling its delivery business, Elan Drug Technologies (EDT).
A reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.
Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec.
The retirement of Biogen Idec’s CEO and appointments at Dishman and Noven – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
FDA approves high titre manufacture of Tysabri
The FDA has approved Biogen Idec to manufacture Tysabri using a high titre process but the product’s sales have been “negatively impacted” by the cases of patients developing PML.
Elan cuts staff and offices as Tysabri wavers
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
Specialists turn to R&D in tough economic times
As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Enzon may sell Indy plant alongside specialty pharma
Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Biotech acquisitions scale new heights
Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
Biogen Idec shares nosedive after withdrawing 'for sale' sign
Like countless pets after every Christmas, it seems that nobody
wanted Biogen Idec after all; the firm has announced it will remain
independent after it 'did not receive any definitive offers to
purchase the company'.
Billionaire 'raider' circles as Biogen put up for sale
Biogen Idec has announced it is seeking a buyer for the company and
has already received several expressions of interest - including a
reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl
Biogen bags two discovery partnerships
Biogen Idec has bagged two new partnerships in the past week which
will see it involved in the search for new drugs for central
nervous system (CNS) and inflammatory ailments.
Biogen dips toe in Indian waters
US-based biotech firm Biogen Idec has decided to enter the booming
Indian market and establish its presence in the country.
Billionaire to get bigger Biogen stake?
Investment mogul Carl Icahn could get ready to buy further shares
of biotech company Biogen Idec after getting the green light from
the competition regulators.